Oxford, UK – 03 February 2015. OGT, The Molecular Genetics Company, explores how Sheffield Children's NHS Foundation Trust has seamlessly transferred to its CytoSure® ISCA 8x60k platform, in a new case study entitled Evaluating and switching to CytoSure microarrays. As the result of a highly stringent National Health Service (NHS) tender for the supply of oligo-based cytogenetics research arrays, CytoSure was selected based on the quality of data and analysis software. In fact, it was the only platform able to correctly identify all the genetic abnormalities tested. The case study follows Consultant Clinical Scientist at Sheffield Children's NHS Foundation Trust, Kath Smith, as she discusses her laboratory’s positive experience of switching to OGT.
Microarray technology is now a routine part of the clinical research workflow; however, advancing array design and analysis capabilities mean that identifying the best platform and supplier can be challenging. As such, the NHS carried out a comprehensive comparison of multiple array platforms in order to select the most effective solution, considering quality of results, ease of use and cost, via a consortium led by four prominent laboratories. Chosen over alternative array suppliers, the success of OGT’s CytoSure ISCA array, designed in partnership with the International Collaboration for Clinical Genomics (ICCG)*, was attributed to a combination of the array and CytoSure Interpret Software performance. Every lab submitted a set of challenging samples to be processed by OGT, and the results came back clean and clear, with the data interpretation software greatly facilitating analysis.
Maintaining productivity within the laboratory, OGT worked hard to ensure a seamless transfer process. In addition to getting the new system itself up and running, the team also provided on-site operational training, software tutorials and transfer of local legacy data to the CytoSure Interpret Software database. Kath comments: “I can only be extremely positive about the whole process of switching to OGT’s CytoSure platform – so if anyone asks me if it’s worth the time and effort of transferring, the answer is a clear yes.”
James Clough, Executive Vice President Commercial at OGT commented: “It’s a pleasure to welcome Sheffield Children's NHS Foundation Trust to OGT. Customer satisfaction is extremely important to us, so it’s great to get such positive feedback on our products and support. It’s a testament to our team’s hard work and dedication.”
From the practicality of high-throughput plate-based labelling through to enhancing their overall operation in a more cost-effective manner, the Sheffield Children's NHS Foundation Trust has reaped the rewards of switching to the best available microarray platform tested. A three-month data audit has also revealed more accurate aneuploidy calling, leading to fewer uncertain cases and saving time and resources involved in follow-up investigations.
*Formerly known as the International Standards for Cytogenomic Arrays (ISCA) Consortium, the ICCG is a group of leading laboratories and companies that develops evidence-based standards for the design of microarray and next generation sequencing tools.
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
For more information on the Company, please visit our website at ogt.com
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.
CytoSure™ NGS – Combining the benefits of microarrays and NGS in a single assay.Read
Robust panel enables accurate and comprehensive constitutional genetic aberration screening in one assay.Read
Paper published in npj Genomic Medicine demonstrates identification of more reportable CNVs with CytoSure v3 vs traditional array design.Read